Results 81 to 90 of about 32,649 (166)

Adapter-based allogeneic CAR T cells to overcome antigen escape in solid tumors. [PDF]

Front Immunol
Pham PQ, Sodji QH.
europepmc   +1 more source

Revisiting B-cell targeted therapies in rheumatoid arthritis: from paradoxical biology to deep immune reset. [PDF]

Front Immunol
Huang M, Dong F, Liu Q, Lin S.
europepmc   +1 more source

Beyond Hematology-Current Insights into Chimeric Antigen Receptor (CAR) T-Cell Therapy for Skin and Connective Tissue Disorders. [PDF]

Cells
Ciosek A, Hofmann J, Galant K, Marinkovich MP, Wierzbowska A, Ciążyńska M, Bień N, Narbutt J, Lesiak A.   +8 more
europepmc   +1 more source

Bryostatin enhances CD20 CAR-T therapy efficacy against B-cell lymphoma by overcoming trogocytosis-mediated antigen loss. [PDF]

Front Immunol
Wang X, Sun K, Zhang Z, Zhang L, Cui L, Song S, Wei L.   +6 more
europepmc   +1 more source

Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial. [PDF]

Blood Adv
Balke-Want H, Gödel P, Schmid C, Ayuk F, Friedrichs B, van Heteren P, Holtkamp S, Zadoyan G, Brillant C, Costa J, Hanssens L, Holzer T, Wöhle C, Biedermann S, Bürger I, Orentas R, Overstijns T, Scheid C, Holtick U, Miltenyi S, Hallek M, Borchmann P, Kutsch N.   +22 more
europepmc   +1 more source

Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review. [PDF]

Front Immunol
Aureli A, Lanzilli G, Boccadamo Pompili SV, Spagnoli GC, Sconocchia G, Caratelli S.   +5 more
europepmc   +1 more source

Engineering programmable CAR and antigen pairing via drug-gated light activation. [PDF]

Nat Commun
Huang Z, Limsakul P, Wu Y, Guo T, Wang Y, Wu Z, Zhu L, Allen ME, Liu L, Wang Y.   +9 more
europepmc   +1 more source

T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives. [PDF]

Front Immunol
Muthughavi K, Khokhar M, Jha HC, Pandey RK.   +3 more
europepmc   +1 more source

A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. [PDF]

J Hematol Oncol
Wang L, Liu J, Zhou K, Li Z, Zeng Y, Qian Y, Sun Y, Wu H, Roerker L, Tan P, Ma C, Zhou L, Duan X, Kang X, Zhao WL.   +14 more
europepmc   +1 more source